370 related articles for article (PubMed ID: 25741816)
1. Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole.
Gandorfer A; Benz MS; Haller JA; Stalmans P; Pakola SJ; Girach A; Kampik A; Toth CA; Jaffe GJ;
Retina; 2015 Jun; 35(6):1151-7. PubMed ID: 25741816
[TBL] [Abstract][Full Text] [Related]
2. Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials.
Varma R; Haller JA; Kaiser PK
JAMA Ophthalmol; 2015 Sep; 133(9):997-1004. PubMed ID: 26068086
[TBL] [Abstract][Full Text] [Related]
3. Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome.
Singh RP; Li A; Bedi R; Srivastava S; Sears JE; Ehlers JP; Schachat AP; Kaiser PK
Br J Ophthalmol; 2014 Mar; 98(3):356-60. PubMed ID: 24357495
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials.
Haller JA; Stalmans P; Benz MS; Gandorfer A; Pakola SJ; Girach A; Kampik A; Jaffe GJ; Toth CA;
Ophthalmology; 2015 Jan; 122(1):117-22. PubMed ID: 25240630
[TBL] [Abstract][Full Text] [Related]
5. Visual Function Response to Ocriplasmin for the Treatment of Vitreomacular Traction and Macular Hole: The OASIS Study.
Lescrauwaet B; Duchateau L; Verstraeten T; Jackson TL
Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5842-5848. PubMed ID: 29141079
[TBL] [Abstract][Full Text] [Related]
6. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
[TBL] [Abstract][Full Text] [Related]
7. Ocriplasmin-Induced Macular Hole Closure in the Absence of Vitreomacular Adhesion Release.
Modi YS; Singh RP
Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):677-9. PubMed ID: 26114851
[TBL] [Abstract][Full Text] [Related]
8. Safety of intravitreal ocriplasmin for focal vitreomacular adhesion in patients with exudative age-related macular degeneration.
Novack RL; Staurenghi G; Girach A; Narendran N; Tolentino M
Ophthalmology; 2015 Apr; 122(4):796-802. PubMed ID: 25435217
[TBL] [Abstract][Full Text] [Related]
9. Improved efficacy of ocriplasmin for vitreomacular traction release and transient changes in optic disk morphology.
Willekens K; Abegão Pinto L; Vandewalle E; Stalmans I; Stalmans P
Retina; 2015 Jun; 35(6):1135-43. PubMed ID: 25719990
[TBL] [Abstract][Full Text] [Related]
10. Incomplete release of vitreomacular attachments after intravitreal ocriplasmin.
Jeng KW; Baumal CR; Witkin AJ; Witkin SR; Wiegand TW; Waheed NK
Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):271-4. PubMed ID: 25707057
[TBL] [Abstract][Full Text] [Related]
11. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
Stalmans P; Benz MS; Gandorfer A; Kampik A; Girach A; Pakola S; Haller JA;
N Engl J Med; 2012 Aug; 367(7):606-15. PubMed ID: 22894573
[TBL] [Abstract][Full Text] [Related]
12. Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole.
Quezada-Ruiz C; Pieramici DJ; Nasir M; Rabena M; Steinle N; Castellarin AA; Dhoot D; Couvillion S; See RF; Avery RL
Retina; 2015 Jun; 35(6):1144-50. PubMed ID: 25961122
[TBL] [Abstract][Full Text] [Related]
13. ASSESSMENT OF ANATOMICAL AND FUNCTIONAL OUTCOMES WITH OCRIPLASMIN TREATMENT IN PATIENTS WITH VITREOMACULAR TRACTION WITH OR WITHOUT MACULAR HOLES: Results of OVIID-1 Trial.
Tadayoni R; Holz FG; Zech C; Liu X; Spera C; Stalmans P
Retina; 2019 Dec; 39(12):2341-2352. PubMed ID: 30308558
[TBL] [Abstract][Full Text] [Related]
14. Early evolution of the vitreomacular interface and clinical efficacy after ocriplasmin injection for symptomatic vitreomacular adhesion.
Meyer JC; Shah GK; Blinder KJ; Waheed NK; Reichel E; Stalmans P; Singer M; Tewari A
Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):209-16. PubMed ID: 25707046
[TBL] [Abstract][Full Text] [Related]
15. Delayed full-thickness macular hole closure without vitreomacular traction release following ocriplasmin injection.
Abou Ltaif S; Herbert L
BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26359463
[TBL] [Abstract][Full Text] [Related]
16. Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/traction.
Kaiser PK; Kampik A; Kuppermann BD; Girach A; Rizzo S; Sergott RC
Retina; 2015 Jun; 35(6):1111-27. PubMed ID: 25635577
[TBL] [Abstract][Full Text] [Related]
17. Chronic Serous Macular Detachments and Visual Disturbance Complicating Consecutive Cases of Symptomatic Vitreomacular Adhesion With Macular Hole Treated With Ocriplasmin.
Luttrull JK
Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):976-8. PubMed ID: 26469240
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Anatomic and Visual Function Outcomes in Patients With Full-Thickness Macular Hole in Ocriplasmin Phase 3 Trials.
Dugel PU; Regillo C; Eliott D
Am J Ophthalmol; 2015 Jul; 160(1):94-9.e1. PubMed ID: 25818925
[TBL] [Abstract][Full Text] [Related]
19. The Efficacy and Safety Profile of Ocriplasmin in Vitreomacular Interface Disorders.
Shaikh M; Miller JB; Papakostas TD; Husain D
Semin Ophthalmol; 2017; 32(1):52-55. PubMed ID: 27786583
[TBL] [Abstract][Full Text] [Related]
20. Ocriplasmin for symptomatic vitreomacular adhesion.
Neffendorf JE; Kirthi V; Pringle E; Jackson TL
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD011874. PubMed ID: 29040800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
